This is a preview of subscription content, log in via an institution to check access.
Notes
2017 US dollars
Reference
Wu Q, et al. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer. Oncology Research and Treatment : 18 Mar 2020. Available from: URL: http://doi.org/10.1159/000505932
Rights and permissions
About this article
Cite this article
Bevacizumab plus paclitaxel not cost effective for HER2− MBC. PharmacoEcon Outcomes News 850, 5 (2020). https://doi.org/10.1007/s40274-020-6693-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6693-9